Please assess the completion status of the following clinical trial:

Trial Title: Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, you must meet the following criteria:~* Locally advanced or metastatic breast cancer~* Measurable disease as per RECIST criteria~* No prior chemotherapy in the metastatic breast setting~* Prior chemotherapy and/or hormonal therapy for early stage breast cancer~* Adjuvant Herceptin is allowed~* Prior radiation therapy in either the metastatic or early stage setting~* Patients may have received any number of hormonal therapies~* Age \>18 years~* Only women are eligible for the study~* Able to perform activities of daily living with minimal assistance~* Normal organ and bone marrow function~* Patients who will be receiving Trastuzumab must have normal heart function~* Sign a written informed consent document~Exclusion Criteria:~You cannot participate in this study if any of the following apply to you:~* Received prior chemotherapy for metastatic breast cancer~* Known leptomeningeal carcinomatosis~* Uncontrolled brain metastasis~* Uncontrolled intercurrent illness~* Pregnant or lactating~* History of other non-breast cancer malignancy~* Received prior chemotherapy for early stage breast cancer within 6 months~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).